The pharmaceutical industry calls for an urgent meeting with the competent ministers on hospital recovery, which in 2021 exceeded 55% and should represent 61% of total expenditure this year
We would like to request an urgent meeting with the relevant ministers regarding the drug industry’s concerns of the hospital clawback which in 2021 exceeded 55% and this year is expected to be 61%. The pharmaceutical industry is willing to cooperate with legislation to achieve a reasonable level of reimbursement according to international standards, within legal limits.
Pharmaceutical companies are requesting a meeting with the relevant ministers regarding the hospital clawback which in 2021 exceeded 55% and this year is expected to be 61%. This is a serious issue that cannot be ignored any longer. The price of medicines we pay for has increased more than triple since 2001, but only a small percent of our health care budget is going toward paying for it.
The Pharmaceutical Industry Association of Australia addresses the Minister for Health and the Prime Minister to urge both to reduce the hospital clawback. It is estimated that this year’s pharmaceutical payment rate will be 61% for all drugs, those under the NHMRC code system. This is an increase from 55% that was implemented in the 2017 National Budget Act with no clear rationale for such a harsh change after years of stability across both price and payment
The pharmaceutical industry has informed the relevant ministers that under the current circumstances, the Pharmaceuticals Pricing Authority (PPA) cannot continue operating in a sustainable manner. In order to become financially viable, we require immediate support from the government.
The pharmaceutical industry is requesting a meeting with the relevant ministers to discuss a plan for the clawback of its medical products. In 2021, the hospital clawback of pharmaceutical products exceeded 55% and this year is expected to be 61%.
The pharmaceutical industry is requested to submit a plan for the clawback of hospital drugs to the relevant ministers. This request is motivated by the fact that in 2021 the percentage of these drugs in total expenditure exceeded 55% and this year is expected to be 61%.
The pharmaceutical industry has been requesting an urgent meeting with the relevant ministers since 2021 and this year it exceeded 55% of the total expenditure, which is worrisome. This must be stopped before it continues to grow, as it could have consequences for the healthcare sector with loss ofpatient trust and relevance in the market place
The pharmaceutical industry would like to raise concerns regarding the importance of government meeting its commitment and funding the reimbursement of hospital drugs under the National Pharmaceutical Pricing Authority (NPPA) Policy for 2018-2019.
